

Special Issue

Kinase Inhibitors 2021

Message from the Guest Editor

In the last decade, about 300 protein kinase inhibitors have been involved in clinical trials and 49 were recently approved by the US Food and Drug Administration (FDA), mostly tyrosine kinase inhibitors, and mainly for cancer therapy. In the same period, targeting kinase pathways has emerged as a promising strategy in the fight against infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites, or fungi. Protein kinase inhibitors were also considered as potential drugs to combat CNS disorders. This Special Issue will showcase the recent trends in the field of drug discovery of kinase inhibitors. In addition, review articles, research articles, and short communications will highlight the efforts of medicinal chemists to propose new molecules endowed with kinase inhibition properties and the strategies to enhance the activity profile of the existing pipeline. Repurposing human kinase inhibitors also gained attention to create new active compounds.

Guest Editor

Prof. Dr. Pascal Marchand

Cibles et Médicaments des Infections et de L'immunité, IICiMed, UR 1155, Nantes Université, F-44000 Nantes, France

Deadline for manuscript submissions

closed (31 July 2021)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.3
Indexed in PubMed



mdpi.com/si/53982

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.3
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).